Suppr超能文献

相似文献

1
Structure-based view of epidermal growth factor receptor regulation.
Annu Rev Biophys. 2008;37:353-73. doi: 10.1146/annurev.biophys.37.032807.125829.
2
Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system.
J Biol Chem. 2010 Mar 5;285(10):7035-44. doi: 10.1074/jbc.M109.096032. Epub 2009 Dec 18.
3
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Nature. 2007 Nov 29;450(7170):741-4. doi: 10.1038/nature05998.
4
Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein.
J Biol Chem. 2011 May 27;286(21):18756-65. doi: 10.1074/jbc.M110.206193. Epub 2011 Mar 30.
5
Molecular determinants of epidermal growth factor binding: a molecular dynamics study.
PLoS One. 2013;8(1):e54136. doi: 10.1371/journal.pone.0054136. Epub 2013 Jan 24.
7
Ligand-induced structural transitions in ErbB receptor extracellular domains.
Structure. 2007 Aug;15(8):942-54. doi: 10.1016/j.str.2007.06.013.
8
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains.
Cell. 2002 Sep 20;110(6):775-87. doi: 10.1016/s0092-8674(02)00963-7.
9
Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3.
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21608-13. doi: 10.1073/pnas.0912101106. Epub 2009 Dec 9.
10
Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains.
Structure. 2013 Jul 2;21(7):1214-24. doi: 10.1016/j.str.2013.05.008. Epub 2013 Jun 20.

引用本文的文献

2
Evaluating the Effectiveness of Tyrosine Kinase Inhibitors on EGFR Mutations In Vitro.
Int J Mol Sci. 2025 Jun 26;26(13):6157. doi: 10.3390/ijms26136157.
4
Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations.
J Transl Med. 2025 May 30;23(1):600. doi: 10.1186/s12967-025-06589-x.
5
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency.
Proc Natl Acad Sci U S A. 2025 Jun 3;122(22):e2425781122. doi: 10.1073/pnas.2425781122. Epub 2025 May 30.
7
Imaging Ligand-Receptor Interactions at Single-Protein Resolution with DNA-PAINT.
Small Methods. 2025 Jun;9(6):e2401799. doi: 10.1002/smtd.202401799. Epub 2025 Apr 3.
8
9
Structural basis for the interaction between the Drosophila RTK Sevenless (dROS1) and the GPCR BOSS.
Nat Commun. 2025 Jan 18;16(1):808. doi: 10.1038/s41467-025-55943-6.
10
Diverse perspectives on proteomic posttranslational modifications to address EGFR-TKI resistance in non-small cell lung cancer.
Front Cell Dev Biol. 2024 Dec 24;12:1436033. doi: 10.3389/fcell.2024.1436033. eCollection 2024.

本文引用的文献

1
Ligand-induced structural transitions in ErbB receptor extracellular domains.
Structure. 2007 Aug;15(8):942-54. doi: 10.1016/j.str.2007.06.013.
2
ErbB receptors: from oncogenes to targeted cancer therapies.
J Clin Invest. 2007 Aug;117(8):2051-8. doi: 10.1172/JCI32278.
3
Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor.
Cell. 2007 Jul 27;130(2):323-34. doi: 10.1016/j.cell.2007.05.055.
6
Epidermal growth factor receptor mutations in lung cancer.
Nat Rev Cancer. 2007 Mar;7(3):169-81. doi: 10.1038/nrc2088.
7
The EGF receptor family: spearheading a merger of signaling and therapeutics.
Curr Opin Cell Biol. 2007 Apr;19(2):124-34. doi: 10.1016/j.ceb.2007.02.008. Epub 2007 Feb 20.
8
The insulin and EGF receptor structures: new insights into ligand-induced receptor activation.
Trends Biochem Sci. 2007 Mar;32(3):129-37. doi: 10.1016/j.tibs.2007.01.001. Epub 2007 Feb 5.
9
Structural basis for stem cell factor-KIT signaling and activation of class III receptor tyrosine kinases.
EMBO J. 2007 Feb 7;26(3):891-901. doi: 10.1038/sj.emboj.7601545. Epub 2007 Jan 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验